Lv2
120 积分 2024-09-18 加入
Perioperative strategies for resectable EGFR-Mutant NSCLC: evidence hierarchy and clinical decision-making
1个月前
已完结
The status of tumor mutational burden and immunotherapy
1个月前
已完结
Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis
2个月前
已完结
Liquid biopsies come of age: towards implementation of circulating tumour DNA
3个月前
已完结
EGFR-Mutant NSCLC: Spotlight on Amivantamab
3个月前
已关闭
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC
3个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
3个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
3个月前
已完结
Radioembolization with Yttrium-90 Microspheres for the Treatment of Liver Metastases of Pancreatic Adenocarcinoma: A Multicenter Analysis
5个月前
已完结
Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial
7个月前
已完结
皖公网安备34019202002308
